Dhaval Desai
Corporate Officer/Principal chez IVERIC BIO, INC.
Profil
Dhaval Desai is currently the Chief Development Officer & Senior Vice President at IVERIC bio, Inc. He previously worked as the Global Director-Medical Affairs at Thrombogenics, Inc. from 2011 to 2014.
He also held the position of Vice President-Medical Affairs at Aerpio Therapeutics, Inc. Additionally, Dr. Desai served as the Vice President & Head-US Ophthalmics at Novartis AG from 2018 to 2020.
Prior to that, he was the Chief Strategy Officer & VP-Medical Affairs at Aerpio Pharmaceuticals, Inc. from 2014 to 2018.
Dr. Desai obtained his doctorate degree from Rutgers State University of New Jersey.
Postes actifs de Dhaval Desai
| Sociétés | Poste | Début |
|---|---|---|
| IVERIC BIO, INC. | Corporate Officer/Principal | 01/04/2021 |
Anciens postes connus de Dhaval Desai
| Sociétés | Poste | Fin |
|---|---|---|
| NOVARTIS AG | Corporate Officer/Principal | 01/08/2020 |
| AERPIO PHARMACEUTICALS | Chief Tech/Sci/R&D Officer | - |
Thrombogenics, Inc.
 Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Corporate Officer/Principal | 01/07/2014 |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Chief Tech/Sci/R&D Officer | - |
Formation de Dhaval Desai
| Rutgers State University of New Jersey | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVARTIS AG | Health Technology |
| Entreprise privées | 4 |
|---|---|
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Aerpio Pharmaceuticals, Inc.
 Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Thrombogenics, Inc.
Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Commercial Services |
